INTRODUCTION
age‐related loss of skeletal muscle mass, sarcopenia, hyperglycemia, fractures, Sarcopenia, muscle mass loss, impaired mobility, diabetes
SARCOPENIA, HYPERGLYCEMIA, SARCOPENIA, TYPE 2 DIABETES, COMPLICATIONS, DIABETES
Sarcopenia is the age‐related loss of skeletal muscle mass and strength, which is associated with impaired mobility, falls and fractures, a decline in activities of daily living, and increased risk of deathThe relationship between glycemic control and sarcopenia in individuals with diabetes has been previously noted. For example, hyperglycemia is associated with muscle weaknessCurrently, dapagliflozin, a sodium–glucose cotransporter 2 inhibitor (SGLT2i), is recognized as a novel treatment for both type 1 and type 2 diabetes, and is used as an additional therapy to insulin to improve glycemic control and prevent complications of diabetes. However, muscle mass loss in individuals with type 2 diabetes using SGLT2i has also been observedIn the present study, our group investigated the changes in glycemic control and body composition in individuals with type 1 diabetes after the use of dapagliflozin. We also examined the relationship between glycemic control changes and skeletal muscle changes.